Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JB1V
|
|||
| Drug Name |
Indazole derivative 3
|
|||
| Synonyms |
PMID29473428-Compound-8
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
IOMET PHARMA LTD
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H18ClN5O2
|
|||
| Canonical SMILES |
CC1(CN(CCC12C(=O)NC(=O)N2)C3=CC(=CC4=C3C=NN4)Cl)C
|
|||
| InChI |
1S/C16H18ClN5O2/c1-15(2)8-22(4-3-16(15)13(23)19-14(24)20-16)12-6-9(17)5-11-10(12)7-18-21-11/h5-7H,3-4,8H2,1-2H3,(H,18,21)(H2,19,20,23,24)
|
|||
| InChIKey |
JZDRNRKIZBGYLY-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | . | [1] |
| Tryptophan 2,3-dioxygenase (TDO) | Target Info | . | [1] | |
| Target's Patent Info | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target's Patent Info | [1] | |
| Tryptophan 2,3-dioxygenase (TDO) | Target's Patent Info | [1] | ||
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation | ||||
| L-kynurenine degradation | ||||
| Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
| NAD de novo biosynthesis | ||||
| KEGG Pathway | Tryptophan metabolism | |||
| Metabolic pathways | ||||
| African trypanosomiasis | ||||
| NetPath Pathway | TSLP Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Tryptophan Metabolism | |||
| Reactome | Tryptophan catabolism | |||
| WikiPathways | Tryptophan metabolism | |||
| Metabolism of amino acids and derivatives | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.